Global Exporter & Bulk Supplier of Bortlieva 3.5 mg Injection

🌍 Introduction

Are you seeking a trusted, globally compliant exporter of Bortlieva 3.5 mg Injection? At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we specialize in the secure, efficient, and compliant distribution of critical oncology formulations. We supply Bortezomib 3.5 mg injections to hospitals, specialized oncology clinics, and pharmaceutical wholesalers across the USA, UK, Australia, and South Africa.

🔬 1. Product Overview: Bortlieva 3.5 mg Injection

Bortlieva 3.5 mg Injection contains Bortezomib, a high-potency antineoplastic agent that serves as a cornerstone in the treatment of plasma cell malignancies.

• Composition: Bortezomib 3.5 mg (as a sterile lyophilized powder)

• Therapeutic Class: Proteasome Inhibitor / Antineoplastic Agent

• Formulation Type: Single-dose vial for reconstitution

• Administration: Intravenous (IV) bolus or Subcutaneous (SC) injection

⚙️ 2. Mechanism of Action

Bortlieva works through a targeted biological mechanism to eliminate cancer cells:

• Proteasome Inhibition: Bortezomib is a reversible inhibitor of the 26S proteasome. Proteasomes are protein complexes that act like "cellular garbage disposals," breaking down unneeded or damaged proteins.

• Intracellular Stress: By blocking these proteasomes, pro-apoptotic proteins and misfolded proteins accumulate within the cancer cell.

• Targeted Apoptosis: This toxic buildup disrupts several signaling pathways, eventually triggering programmed cell death (apoptosis) in malignant cells while sparing many healthy cells.

🏥 3. Therapeutic Indications

Bortlieva 3.5 mg Injection is clinically indicated for:

• Multiple Myeloma: Used for newly diagnosed patients (often in combination with drugs like dexamethasone or melphalan) and for patients who have relapsed after prior therapy.

• Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma who have received at least one prior therapy.

⚠️ 4. Administration & Safety Guidelines

• Professional Use Only: Must be administered by a healthcare professional experienced in chemotherapy.

• Dual Route: Can be given via Intravenous (IV) or Subcutaneous (SC) injection.

• Strict Warning: NOT FOR INTRATHECAL USE. Administration into the spinal fluid is fatal.

• Common Side Effects: Nausea, diarrhea, thrombocytopenia (low platelet count), fatigue, and peripheral neuropathy (tingling/numbness in extremities).

• Monitoring: Patients should undergo regular blood tests to monitor complete blood counts (CBC) and liver/kidney function.